United Kingdom· GB-APID-19486311000001101
Rapiscan 400micrograms/5ml solution for injection vials
A regadenoson product containing regadenoson, registered in United Kingdom by GE Healthcare Ltd. The same ATC class is registered in 13 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Regadenoson is registered in 13 of 19 countries.
Countries holding a registration under ATC C01EB21 (regadenoson), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 9 of them publish a price we can compare per daily dose
Regadenoson · ATC C01EB21
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Regadenoson
- Manufacturer
- GE Healthcare Ltd
- Country
- United Kingdom (GB)
- ATC code
- C01EB21
- ATC class
- Regadenoson
- Defined daily dose
- 0.4 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 2
- gtin5060265060008
- gtin5060265060084
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
6 interactions on record for regadenoson.
Graded by severity as the source publishes them — 6 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Regadenoson · interactions on record
6 records
- 6 moderate
Most severe, free to view
- DipyridamoleB01AC07moderate
- DipyridamolC01DX29moderate
- TheophyllinC01EB28moderate
- CaffeineN06BC01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Regadenoson in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesLEXISCANAstellas Pharma US, Inc.
- FinlandRapiscanAbacus Medicine A/S
- CzechiaRAPISCANGE Healthcare AS, Oslo
- SpainRapiscan 400mcg solucion inyectableGe Healthcare As
- FranceRAPISCAN 400 microgrammes, solution injectableGE HEALTHCARE (NORVEGE)
- BelgiumRapiscan 400 µgGE Healthcare
- IcelandRapiscanGE Healthcare AS
- NetherlandsRapiscan 400 microgram oplossing voor injectieGE Healthcare AS
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Rapiscan
- Liechtenstein · Rapiscan
- Norway · Rapiscan
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0cdf3b54-560f-410f-9cb4-c1f15b047ef3 GET /v1/drugs/0cdf3b54-560f-410f-9cb4-c1f15b047ef3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "19486311000001101",
"desc": "Rapiscan 400micrograms/5ml solution for injection vials (GE Healthcare Ltd)",
"form": "Solution for injection",
"vpid": "19486211000001109",
"source": "dmd",
"vtm_id": "777415006",
"strength": "80 microgram",
"substance": "Regadenoson",
"ingredient": "Regadenoson",
"supplier_code": "11269611000001107"
}See everything about regadenoson.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.